...
机译:保利(腺苷Diphosphate-Ribose)的状态聚合酶(PARP)抑制剂在卵巢癌,第2部分:扩展了除了Olaparib和范围BRCA1/2突变
University College London Hospital in London, the United Kingdom;
Recombinational DNA Repair; Status; Ovary CancerpolyadenosineOlaparibPoly(ADP-ribose) Polymerase InhibitorsHomologous Recombination;
机译:Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
机译:Poly (adenosine diphosphate ADP-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis
机译:RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors